{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:48:36Z","timestamp":1771930116031,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms when eligibility criteria were met (Part A). In Part B, patients who declined randomization could choose the study arm. In Part A, 69 (21.8%) of 317 patients were randomized; 78.2% were not randomized because of non-targetable alterations (39.8%), unavailability of clinical trial (21.8%), other reasons (12.6%), or availability of US Food and Drug Administration (FDA)-approved drugs for the indication (4.1%). In Part B, 32 (20.4%) of 157 patients were offered randomization; 16 accepted and 16 selected their treatment arm; 79.0% were not randomized (patient\u2019s\/physician\u2019s choice, 29.3%; treatment selection prior to genomic reports, 16.6%; worsening performance status\/death, 12.7%; unavailability of clinical trials, 6.4%; other, 6.4%; non-targetable alterations, 5.7%; or availability of FDA-approved drugs for the indication, 1.9%). In conclusion, although randomized controlled trials have been considered the gold standard for drug development, the execution of randomized trials in precision oncology in the advanced metastatic setting is complicated. We encountered various challenges conducting the IMPACT2 study, a large precision oncology trial in patients with diverse solid tumor types. The adaptive design of IMPACT2 enables patient randomization despite the continual FDA approval of targeted therapies, the evolving tumor biomarker landscape, and the plethora of investigational drugs. Outcomes for randomized patients are awaited.<\/jats:p>","DOI":"10.1038\/s41698-022-00317-0","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:08:12Z","timestamp":1666897692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology"],"prefix":"10.1038","volume":"6","author":[{"given":"Henry Hiep","family":"Vo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-0629","authenticated-orcid":false,"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6202-6113","authenticated-orcid":false,"given":"Amber","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-4328","authenticated-orcid":false,"given":"I-Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela M.","family":"Nogueras-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Vining","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia-Maria","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"317_CR1","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res 8, 935\u2013942 (2002).","journal-title":"Clin. Cancer Res"},{"key":"317_CR2","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res 18, 6373\u20136383 (2012).","journal-title":"Clin. Cancer Res"},{"key":"317_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00002","author":"AM Tsimberidou","year":"2017","unstructured":"Tsimberidou, A. M. et al. Initiative for Molecular Profiling and advanced Cancer Therapy (IMPACT): an MD Anderson precision medicine study. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.17.00002 (2017).","journal-title":"JCO Precis Oncol."},{"key":"317_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","volume":"21","author":"MH Murad","year":"2016","unstructured":"Murad, M. H., Asi, N., Alsawas, M. & Alahdab, F. New evidence pyramid. Evid. Based Med. 21, 125\u2013127 (2016).","journal-title":"Evid. Based Med."},{"key":"317_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/aogs.13309","volume":"97","author":"A Bhide","year":"2018","unstructured":"Bhide, A., Shah, P. S. & Acharya, G. A simplified guide to randomized controlled trials. Acta Obstet. Gynecol. Scand. 97, 380\u2013387 (2018).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"317_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00159-2","volume":"5","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou, A. M. et al. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 5, 21 (2021).","journal-title":"NPJ Precis Oncol."},{"key":"317_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/CCI.20.00142","volume":"5","author":"NM Jain","year":"2021","unstructured":"Jain, N. M., Culley, A., Micheel, C. M., Osterman, T. J. & Levy, M. A. Learnings from precision clinical trial matching for oncology patients Who received NGS testing. JCO Clin. Cancer Inf. 5, 231\u2013238 (2021).","journal-title":"JCO Clin. Cancer Inf."},{"key":"317_CR8","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1158\/1078-0432.CCR-14-0603","volume":"20","author":"AM Tsimberidou","year":"2014","unstructured":"Tsimberidou, A. M. et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin. Cancer Res 20, 4827\u20134836 (2014).","journal-title":"Clin. Cancer Res"},{"key":"317_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","volume":"12","author":"AM Tsimberidou","year":"2019","unstructured":"Tsimberidou, A. M. et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J. Hematol. Oncol. 12, 145 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"317_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of clinical oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"317_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"317_CR12","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/ijc.32358","volume":"145","author":"J Leichsenring","year":"2019","unstructured":"Leichsenring, J. et al. Variant classification in precision oncology. Int J. Cancer 145, 2996\u20133010 (2019).","journal-title":"Int J. Cancer"},{"key":"317_CR13","first-page":"1","volume":"3","author":"J Zeng","year":"2019","unstructured":"Zeng, J. et al. Operationalization of next-generation sequencing and decision support for precision oncology. JCO Clin. Cancer Inf. 3, 1\u201312 (2019).","journal-title":"JCO Clin. Cancer Inf."},{"key":"317_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"317_CR15","doi-asserted-by":"publisher","unstructured":"Chen, A. P. et al. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): a randomized multicenter phase II trial. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.20.00372 (2021).","DOI":"10.1200\/PO.20.00372"},{"key":"317_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751\u2013758 (2019).","journal-title":"Nat. Med."},{"key":"317_CR17","unstructured":"American Society of Clinical Oncology. Targeted Agent and Profiling Utilization Registry (TAPURTM) Study. https:\/\/www.tapur.org\/ (2020)."},{"key":"317_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","volume":"76","author":"AM Tsimberidou","year":"2015","unstructured":"Tsimberidou, A. M. Targeted therapy in cancer. Cancer Chemother. Pharmacol. 76, 1113\u20131132 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"317_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"317_CR20","doi-asserted-by":"publisher","first-page":"175883592110015","DOI":"10.1177\/17588359211001538","volume":"13","author":"MF Naqvi","year":"2021","unstructured":"Naqvi, M. F., Vo, H. H., Vining, D. & Tsimberidou, A. M. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther. Adv. Med. Oncol. 13, 17588359211001538 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"317_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cllc.2020.05.029","volume":"21","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou, A. M., Elkin, S., Dumanois, R. & Pritchard, D. Clinical and economic value of genetic sequencing for personalized therapy in non-small-cell lung cancer. Clin. Lung Cancer 21, 477\u2013481 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"317_CR22","doi-asserted-by":"publisher","unstructured":"Meric-Bernstam, F. et al. A decision support framework for genomically informed investigational cancer therapy. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv098 (2015).","DOI":"10.1093\/jnci\/djv098"},{"key":"317_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.drudis.2015.05.013","volume":"20","author":"A Johnson","year":"2015","unstructured":"Johnson, A. et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Disco. Today 20, 1433\u20131438 (2015).","journal-title":"Drug Disco. Today"},{"key":"317_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.316.7128.360","volume":"316","author":"DJ Torgerson","year":"1998","unstructured":"Torgerson, D. J. & Sibbald, B. Understanding controlled trials. What is a patient preference trial? BMJ 316, 360 (1998).","journal-title":"BMJ"},{"key":"317_CR25","unstructured":"Perlmutter, J. Understanding Clinical Trial Design: A Tutorial for Research Advocates. http:\/\/www.lymphomation.org\/CTTutorial.pdf (2004)."},{"key":"317_CR26","doi-asserted-by":"crossref","unstructured":"Porzsolt, F., Sehhouli, J. & Stengel, D. In Optimizing Health: Improving the Value of Healthcare Delivery. 265\u2013297 (Springer: Berlin, 2006).","DOI":"10.1007\/978-0-387-33921-4"},{"key":"317_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry, D. A. Bayesian clinical trials. Nat. Rev. Drug Discov. 5, 27\u201336 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"317_CR28","doi-asserted-by":"crossref","unstructured":"Gelman, A., Carlin, J. B., Stern, H. S. & Rubin, D. B. Bayesian Data Analysis 2nd edn (CRC Press, 2004).","DOI":"10.1201\/9780429258480"},{"key":"317_CR29","doi-asserted-by":"crossref","unstructured":"Carlin, B. P. & Louis, T. A. Bayesian Methods for Data Analysis 3rd edn (Bo CRC Press, 2008).","DOI":"10.1201\/b14884"},{"key":"317_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03252-y","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. Cancer Immunol. Immunother. https:\/\/doi.org\/10.1007\/s00262-022-03252-y (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"317_CR31","unstructured":"Tempus. Genomic Profiling. https:\/\/www.tempus.com\/oncology\/genomic-profiling\/ (2022)."},{"key":"317_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","volume":"37","author":"N Beaubier","year":"2019","unstructured":"Beaubier, N. et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat. Biotechnol. 37, 1351\u20131360 (2019).","journal-title":"Nat. Biotechnol."},{"key":"317_CR33","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.26797","volume":"10","author":"N Beaubier","year":"2019","unstructured":"Beaubier, N. et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 10, 2384\u20132396 (2019).","journal-title":"Oncotarget"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00317-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T17:58:52Z","timestamp":1701280732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00317-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1038\/s41698-022-00317-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.-M.T. Clinical Trial Research Funding (received through the institution): OBI Pharma, IMMATICS, Parker Institute for Cancer Immunotherapy, Agenus, Tempus, Tvardi, Boston Biomedical, Karus Therapeutics; Consulting or Advisory Role: Vincerx, Diaccurate, BrYet. V.S. reports grants from Eli Lilly\/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals; and grants from Helsinn Pharmaceuticals during the conduct of the study; in addition, V. Subbiah reports a grant and advisory board\/consultant position with Eli Lilly\/Loxo Oncology during the conduct of the study; research grants from Roche\/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, Medimmune; an advisory board\/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Roche, Medimmune; travel funds from Pharmamar, Incyte, ASCO, ESMO; other support from Medscape; all outside the submitted work. A.N. Consulting or Advisory Role: Novartis, CytomX Therapeutics, OncoSec, STCube Pharmaceuticals Inc, Kymab, Takeda (I), CSL Behring (I), Horizon Pharma (I), Genome & Company, Immune-Onc, Deka Bioscience, Nouscom. Research Funding (to the institution): NCI, EMD Serono, MedImmune, Atterocor, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance BioSciences Inc, Healios, Lilly, Kymab, PsiOxus Therapeutics, Immune Deficiency Foundation (I), Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, Baxalta (I), Jeffrey Modell Foundation (I), Chao Physician-Scientist Awards (I). Travel, Accommodations, Expenses: ARMO BioSciences. D.D.K. Clinical Trials. Paid to Institution: Phosplatin Therapeutics, Pfizer, Arcus, Arqule, Bristol-Myers Squibb, Eli Lilly, Five Prime Therapeutics, Glaxo Smith Kline, Genmab, Holy Stone Healthcare Co., Ipsen, Mirati Therapeutics, Inc., Novartis, Onco Response, Red Hill Biopharma Ltd., Rgenix, Sanofi-Aventis, Xencor, Astellas, Janssen, Affigen, Black Beret Life Sciences, NIH Clinical Translational Science Award Grant. D.S.H. Research\/Grant Funding through the institution from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai,Endeavor, Erasca, F. Hoffmann-La Roche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda,TCR2, Teckro, Turning Point Therapeutics, Verstatem, VM Oncology. Consulting fees from Adaptimmune, Alpha Insights, Acuta, Alkermes, Amgen, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, COR2ed, COG, Ecor1, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point, WebMD, Ziopharm. Travel\/Accommodations\/Expenses: from Bayer, Genmab, AACR, ASCO, SITC, Telperian; Other ownership interests include Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder,Advisor). D.J.V. is the CEO and majority owner of VisionSR and an inventor of Bracco Diagnos-tics. D.A.B. Other ownership interests: co-owner of Berry Consultants, LLC, a company that designs adaptive Bayesian clinical trials for pharmaceutical and medical device companies, National Institutes of Health cooperative groups, international consortia, and patient advocacy groups. F.J. Research\/Grant Funding (received through the institution): support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Novellus and Proximagen; is or has been on the Scientific Advisory Boards for Bicara, Guardant Health, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. Current position: Chief Medical Officer\u2014Monte Rosa Therapeutics. F.M.-B. Consulting: AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks. Advisory Committee: Black Diamond, Biovica, Eisai, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis. Sponsored Research (to the institution): Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co. Honoraria: Chugai Biopharmaceuticals. Other (Travel Related): None. J.R. Research Funding\u2014Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli, Vall d\u2019Hebron Institute of Oncology\/Cancer Core Europe. Clinical Research\u2014Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bycicle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics. Support for attending meetings and\/or travel: European Society for Medical Oncology. Monitoring Board or Advisory Board: Advisory Board\u2014Peptomyc, Kelun Pharmaceuticals\/Klus Pharma, Ellipses Pharma, Molecular Partners, IONCTURA. Other financial or non-financial interests: Vall d\u2019Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC. S.P.-P. receives Research\/Grant Funding through the institution from the following sources: AbbVie, Inc.; ABM Therapeutics, Inc.; Acepodia, Inc; Alkermes; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol-Myers Squib; Cerulean Pharma, Inc.; Chugai Pharmaceutical Co., Ltd; Curis, Inc.; Cyclacel Pharmaceuticals; Daiichi Sankyo; Eli Lilly; ENB Therapeutics; Five Prime Therapeutics; F-Star Beta Limited; F-Star Therapeutics; Gene Quantum; Genmab A\/S; Gilead Sciences, Inc.; GlaxoSmithKline; Helix BioPharma Corp.; HiberCell, Inc.; Immunomedics, Inc.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Lytix Biopharma AS; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Purinomia Biotech, Inc.; Rapt Therapeutics, Inc.; Seattle Genetics; Silverback Therapeutics; Synlogic Therapeutics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; ZielBio, Inc.; NCI\/NIH; P30CA016672\u2014Core Grant (CCSG Shared Resources). She has additionally worked as a consultant for CRC Oncology. S.F. Clinical Trial Research Support\/Grant Funding through the institution from the following sources: NIH\/NCI P30CA016672\u2014Core Grant (CCSG Shared Resources); Abbisko; BeiGene; BioAtla, LLC.; Boehringer Ingelheim; Eli Lilly & Co.; Exelisis; Greenfire Bio, Inc.; Hookipa Biotech; IMV, Inc.; Innovent Biologics, Co., Ltd.; K-Group Beta; Lyvgen Biopharm, Co., Ltd.; MacroGenics; Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; NextCure, Inc.; Ningbo NewBay Technology Development Co., Ltd.; Novartis; NovoCure; Parexel International, LLC; Pionyr Immunotherapeutics, Inc.; PureTech Health, LLC; Sellas Life Sciences Group; Soricimed Biopharma, Inc.; SQZ Biotechnologies; Sumitomo Dainippon; Taiho Oncology and NCCN; Treadwell Therapeutics; Turnstone Biologics; Tyligand Bioscience, Ltd.; Nykode Therapeutics AS. T.A.Y. Employment: University of Texas MD Anderson Cancer Center, where I am Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios). Grant\/Research support (to Institution): Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenith. Consultancies: AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, Bristol-Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio. Stockholder in: Seagen. V.M. Patent Royalties: Memorial Sloan Kettering Cancer Center, USPO 850141. Stock Holder: Foundation Medicine\/ROCHE; EQRX; Mirati Therapeutics. Other Compensation: Board of Directors, Revolution Medicines; EQRX Employee. C.C. holds a senior leadership position (Sr Vice President, Medical Affairs, Tempus Labs, Inc), received compensation, and holds stock in Tempus Labs, Inc. Chicago, IL. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}